Altimmune to Announce Third Quarter 2020 Financial Results on November 10
Rhea-AI Summary
Altimmune, Inc. (Nasdaq: ALT) announced it will release its third quarter 2020 financial results on November 10, 2020. A conference call for investors will follow at 8:30 a.m. ET on the same day, where management will discuss the financial results and provide a business update. The company, focused on developing intranasal vaccines and therapies, has a diverse pipeline including products for COVID-19, anthrax, and liver disease. For more details, investors can access the conference call via a webcast.
Positive
- Diverse pipeline including vaccines for COVID-19 and other diseases.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ALT gained 2.64%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter 2020 financial results on Tuesday, November 10, 2020.
Altimmune management will host a conference call for investors beginning at 8:30 a.m. ET on Tuesday, November 10, 2020 to discuss the financial results and provide a business update.
Conference Call Details
| Date: | Tuesday, November 10th |
| Time: | 8:30 am Eastern Time |
| Domestic: | 877-300-8521 |
| International: | 412-317-6026 |
| Conference ID: | 10149733 |
| Webcast: | http://public.viavid.com/index.php?id=142319 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.
| Investor Contacts: | ||
| Will Brown | Ashley R. Robinson | |
| Chief Financial Officer | LifeSci Advisors, LLC | |
| Phone: 240-654-1450 | 617-430-7577 | |
| wbrown@altimmune.com | arr@lifesciadvisors.com | |
| Media Contacts: | ||
| Warren Rizzi | ||
| Sard Verbinnen & Co. | ||
| Phone: 212-687-8080 | ||
| altimmune-svc@sardverb.com |
FAQ
When will Altimmune release its third quarter 2020 financial results?
What time is the Altimmune investor conference call?
What is Altimmune's focus in their product pipeline?
How can investors access the Altimmune conference call?
